KROS (Keros Therapeutics) Tariff Resilience Score: 8/10 (As of Jul. 01, 2026)


KROS Keros Therapeutics Inc KROS
30 GF Score
Price $10.88
! 2 Warning Signs
View Full Analysis

What is Keros Therapeutics Tariff Resilience Score?

Keros Therapeutics KROS +1.87% 30 Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, Keros Therapeutics ranks better than 98.69% on this metric.

Keros Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Keros Therapeutics has Keros Therapeutics Inc has a strong domestic focus with limited international supply chain dependencies. The biotech industry benefits from tariff exemptions, and the company has not been significantly impacted by past tariff changes. Its ability to source materials domestically enhances its tariff resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Keros Therapeutics might have Highly Resilient.

Keros Therapeutics  (NAS:KROS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Keros Therapeutics Tariff Resilience Score Related Terms

KROS vs CDXS, CAMP, VYGR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Keros Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's Tariff Resilience Score falls into.


KROS
30GF Score
Keros Therapeutics Inc KROS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Keros Therapeutics (KROS) has a Tariff Resilience Score of 8 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Keros Therapeutics ranks #18 out of 1374 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Keros Therapeutics' Tariff Resilience Score too high?
Keros Therapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Keros Therapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, Keros Therapeutics ranks #18 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Tariff Resilience Score compare to CDXS and CAMP?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #18 out of 1374 companies for Tariff Resilience Score. This places Keros Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Keros Therapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keros Therapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.88
Price